Search Results

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.

Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders (“Annual Meeting”), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.

Aridis Pharmaceuticals, Inc. (OTCQB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2023.

Aridis Pharmaceuticals, Inc. today announced the pricing of an offering of 10,000,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase up to 10,000,000 shares of common stock at a combined offering price of $0.20 per share.

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today reported financial and corporate results for its first quarter ended March 31, 2023.

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced a corporate update on recent developments.

Aridis Pharmaceuticals, Inc. today announced that its AR-301 clinical program has been deemed eligible for consideration under the U.S. Food and Drug Administration’s (FDA) Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD).

Aridis Pharmaceuticals, Inc., a biopharmaceutical company, announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on May 23, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission.

Aridis Pharmaceuticals, Inc. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 6,000,000 shares of the Company’s common stock at a purchase price of $0.38 per share in a registered direct offering.

Aridis Pharmaceuticals, Inc. announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 19, 2023 indicating that the Company is not currently in compliance with Nasdaq’s Listing Rules due to the Company’s inability to timely file its Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission.